What's New What's New/Press Release

Embassy of India, Jakarta

Indian Pharma Industry interaction with Indonesian Health Minister

 

An interactive meeting of Indian pharma companies and Indian professionals in Indonesian Pharma Sector took place with H.E. Mr Terawan Agus Putranto, Minister of Health of Indonesia in the Ministry of Health, Jakarta on 27th January, 2020. The objective of the interaction was to enhance cooperation in pharmaceutical sector between India and Indonesia and enlarge Indian investments in pharma sector of Indonesia.

 

2. The interaction was attended by senior representatives of 14 Pharma companies, including 3 Indian companies and the CII Representative in Indonesia, while from the Indonesian Health Ministry, senior officials including Ms. Engko S Magdalene, Director General of Pharmaceutical and Medical Devices, participated.

 

3. In his remarks, H.E. Mr Pradeep Kumar Rawat pointed out to the similarities existing between India and Indonesia in the public health schemes devised and challenges in implementing them, which enables mutual replication of success stories without any gestation period. He remarked that this commonality has also resulted in greater interest in Indonesia to attract investments from India in the Pharmaceutical sector. He hoped that the deliberations, drawing upon the first hand experience of Indian pharma sector, would contribute to a more durable and mutually beneficial partnership between the two countries.

 

4. In his opening remarks, H.E. Mr Terawan Agus Putranto, Minister of Health said that the interaction organized with the Indian pharma sector is one of the programmes aimed at accelerating the implementation of MOU on Health existing between the two countries. He opined that the deliberations would enable discussions among all stakeholders to further strengthen existing cooperation between Indonesia and India in the pharma sector. Minister Putranto also gave an overview of the Indonesian health sector highlighting the priority areas and existing state of healthcare facilities.

 

5. Participating Indian Pharma companies, namely Hetero, NephroPlus and Apollo Hospitals as also the Indian pharma professionals put forward their suggestions to enhance Indian investments in Indonesian Pharma sector by making regulatory changes to speed up procedure for registration of drugs and ease limits for investments in finished formulations and healthcare sector. Promotion of API manufacturing units, through incentives in tax and land, would give a major boost to the local manufacturers, enabling much needed easy integration in processing of the finished formulation.

6. It may be noted that today’s interaction was a follow-up to Ambassador’s courtesy call on the Hon’ble Minister of Health on 6th January, when both sides had agreed to convene an early meeting of pharma and health industry stakeholders.

 

Jakarta,

27th January, 2020